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a b s t r a c t
Current atherosclerosis treatment strategies primarily focus on limiting further cholesteryl esters (CE)
accumulation by reducing endogenous synthesis of cholesterol in the liver. No therapy is currently
available to enhance the removal of CE, a crucial step to reduce the burden of the existing disease. Given
the central role of hepatic cholesteryl ester hydrolase (CEH) in the intrahepatic hydrolysis of CE and
subsequent removal of the resulting free cholesterol (FC), in this work, we applied galactose-
functionalized polyamidoamine (PAMAM) dendrimer generation 5 (Gal-G5) for hepatocyte-speciﬁc de-
livery of CEH expression vector. The data presented herein show the increased speciﬁc uptake of Gal-G5/
CEH expression vector complexes (simply Gal-G5/CEH) by hepatocytes in vitro and in vivo. Furthermore,
the upregulated CEH expression in the hepatocytes signiﬁcantly enhanced the intracellular hydrolysis of
high density lipoprotein-associated CE (HDL-CE) and subsequent conversion/secretion of hydrolyzed FC
as bile acids (BA). The increased CEH expression in the liver signiﬁcantly increased the ﬂux of HDL-CE to
biliary as well as fecal FC and BA. Meanwhile, Gal-G5 did not induce hepatic or renal toxicity. It was also
not immunotoxic. Because of these encouraging pre-clinical testing results, using this safe and highly
efﬁcient hepatocyte-speciﬁc gene delivery platform to enhance the hepatic processes involved in
cholesterol elimination is a promising strategy for the alleviation of atherosclerosis.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
Cardiovascular disease (CVD) continues to be the number one
cause of morbidity and mortality in the Western World including
the USA [1,2]. The most common cause of CVD is atherosclerosis
characterized with deposition of cholesteryl ester (CE)-laden
macrophage foam cells in the arterial wall, a process starting in the
teenage years and progressing silently for years before the mani-
festation of clinical symptoms [3,4]. A common therapeutic strategy
is to reduce plasma cholesterol by restricting cholesterol intake or
reducing de novo cholesterol biosynthesis. The rationale behind this
strategy is to reduce the inﬂux of cholesterol into the macrophages,
hence reducing new foam cell formation and halting the plaque
progression. Nonetheless, to reduce the lipid burden in the existing
plaque, the only plausible way is to enhance the removal of CE from
the macrophage foam cells [5]. Furthermore, reduction in the lipid
core of the plaques may help increase plaque stability, hence likely
reducing acute cardiovascular events such as heart attacks [6].
Although the importance of increasing the ﬂux of cholesterol from
macrophages to the liver for ﬁnal elimination (or reverse choles-
terol transport, RCT) is widely recognized, no therapy is available to
enhance the removal of CE from the existing plaques, facilitate
plaque regression, or increase plaque stability [7].
Under a normal physiological setting, a homeostatic balance
between cholesterol inﬂux (unregulated uptake of modiﬁed low
density lipoprotein (mLDL)) and efﬂux (removal of un-esteriﬁed or
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free cholesterol (FC) by apolipoprotein A1, ApoA1 or high density
lipoprotein (HDL)) restricts pathological accumulation of CE in
macrophages. However, a disrupted balance between cholesterol
inﬂux and efﬂux leads to excessive accumulation of CE within the
macrophage foam cells, causing pathological consequences. With
the failure to show any therapeutic improvement in clinical trials
aimed at increasing HDL cholesterol by niacin (AIM-HIGH and
HPS2-THRIVE (Heart Protection Study 2-Treatment of HDL to
Reduce the Incidence of Vascular Events)) or cholesteryl ester
transfer protein (CETP) inhibitor [8], focus has recently shifted to
the efﬂux ability of HDL to remove cholesterol from macrophage
foam cells [4]. Correlation between the HDL efﬂux capacity and CVD
has been established clinically [9e11]. It must be noted that
althoughmacrophage foam cells store cholesterol in the form of CE,
only FC is available for efﬂux to ApoA1 or HDL via the membrane
cholesterol transporters ABCA1 (ATP Binding Cassette Subfamily A
Member 1) and ABCG1 (ATP Binding Cassette Subfamily G Member
1), thus making intracellular CE hydrolase (CEH)-mediated con-
version of CE into FC an important and likely rate-limiting step in
cholesterol efﬂux pathway [12,13].
Liver is the central organ for the clearance of cholesterol from
the body. Cholesterol removed from the peripheral organs
including plaque associated macrophages returns to the liver via
HDL, which contains >80% of cholesterol in the form of CE [14]. HDL
receptor scavenger receptor class B type I (SR-BI) on the hepatocyte
surface facilitates the selective delivery of HDL-associated CE (HDL-
CE) and FC.While HDL-FC is thought to be rapidly secreted into bile,
the fate of HDL-CE is not completely deﬁned [7]. We have
conﬁrmed that hepatic CEH plays a central role in HDL-CE hydro-
lysis. We observed that liver-speciﬁc transgenic expression of hu-
man liver CEH enhanced the ﬂux of HDL-CE to bile and feces and
reduced Western-diet induced atherosclerosis [15e17]. Enhanced
bile acid secretion was found to reduce the CVD risk [18,19]. These
studies validated the unidirectional ﬂux of cholesterol from
macrophage foam cells to the liver and to bile/feces as an anti-
atherogenic step. Therefore, novel anti-atherogenic agents can be
developed to promote hepatic hydrolysis of HDL-CE. Liver-speciﬁc
delivery of CEH gene represents one such approach.
With these concepts in mind, here we used polyamidoamine
(PAMAM) dendrimer generation 5 (G5) to design a hepatocyte-
speciﬁc delivery system to deliver CEH expression vector and
enhance its expression in the liver so as to increase the ﬁnal
elimination of cholesterol (See Scheme 1). PAMAM dendrimers
have distinct merits as non-viral gene delivery vectors, including
well-deﬁned nanoscale spherical architecture, large number of
surface amine groups capable of efﬁciently complexing with genes
through electrostatic interactions, as well as endosomal-lysosomal
escape ability due to the proton-sponge effect [20e23]. Moreover,
PAMAM dendrimers have been widely modiﬁed with various
targeted ligands, such as carbohydrate moieties [24], antibodies
[25], peptides [26] and aptamers [27] to enhance targeting spec-
iﬁcity. Although the majority of cells (60e80%) in the liver are
parenchymal hepatocytes, most nanoparticles are typically taken
up by non-parenchymal Kupffer cells (mononuclear phagocyte
system, MPS) [28e30]. Thus, maximizing the active uptake by
hepatocytes meanwhile minimizing the passive clearance by the
MPS in the liver is an important consideration for development of
hepatocyte-speciﬁc non-viral gene delivery platforms [31,32].
Taking advantage of hepatocyte-speciﬁc expression of asialogly-
coprotein receptor (ASGPR) and the strong afﬁnity of this receptor
for galactose [33e35], G5 was functionalized with galactose (Gal)
via a long polyethylene glycol (PEG) spacer (35 kDa) to form Gal-
G5, where long PEG spacer will likely reduce the toxicity from the
enormous G5 surface cations. Liver-targeted anticancer drug de-
livery using lactobionic acid-functionalized dendrimers has been
reported [36,37]. For the ﬁrst time, we used Gal-functionalized
PAMAM dendrimer for liver-speciﬁc gene delivery. The data pre-
sented here demonstrate speciﬁc uptake of Gal-G5 by hepatocytes
in vitro and in vivo. Furthermore, we conﬁrmed the ability of Gal-
G5 to efﬁciently deliver CEH expression vector and increase the
hepatic hydrolysis of HDL-CE to FC and subsequently to bile acids.
Development of such a safe, liver hepatocyte-speciﬁc efﬁcient
dendrimer-based delivery system for CEH expression vector offers
a possible solution to regressing the existing atherosclerotic
plaques.
Scheme 1. Design of a hepatocyte-speciﬁc anti-atherogenic gene delivery system. Cholesterol (>80% in the form of CE) is transported by HDL from atherosclerotic plaque-
associated macrophage foam cells to the liver by the process of RCT, subsequently converted to BA, and eliminated from bile/feces. Galactose-functionalized PAMAM dendrimer
G5, i.e., Gal-G5, is developed as a hepatocyte-speciﬁc gene delivery system to deliver CEH expression vector. Galactose facilitates ASGPR-mediated endocytosis of Gal-G5/CEH
complexes into hepatocytes in the liver and increases CEH expression. The overexpressed CEH would enhance the hydrolysis of HDL-CE into FC, which is either directly
secreted into bile or converted to bile acids followed by elimination from the body - a process proposed to regress the existing atherosclerotic plaques.
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2. Materials and methods
2.1. Materials
Ethylenediamine (EDA) core PAMAM dendrimer G5 (technical
grade) was purchased from Dendritech (Midland, MI). Fluorescein
isothiocyanate (FITC) and D-(þ)-galactose were purchased from
Sigma-Aldrich (St. Louis, MO). IRDye 800CW NHS ester was ob-
tained from Li-COR Biotechnology (Lincoln, NE). Galactose-PEG-
NHS (Mn ¼ 35000 g/mol) was purchased from JenKem Technol-
ogy (Plano, TX, USA). SnakeSkin dialysis tubing with 7000 molec-
ular weight cut-off (MWCO) was purchased from Thermo Scientiﬁc
(Rockford, IL). Water soluble tetrazolium-1 (WST-1) reagent was
purchased from Roche Applied Science (Grand Island, NY). Colla-
genase type I was obtained from Worthington Biochemical Corp.
William’s E medium. Fetal bovine serum (FBS) and Dulbecco’s
phosphate-buffered saline (DPBS) were obtained from Gibco BRL
(Carlsbad, CA, USA). Trypsin-EDTA (0.25%), streptomycin and
penicillin were obtained from Invitrogen Co., USA. Label IT® Cy3
control plasmid was purchased from Mirus Bio (Madison, WI).
Vectashield mounting media were purchased from Vector Labora-
tories (Burlingame, CA). RNeasy® Mini Kit was purchased from
QIAGEN GmbH. High Capacity cDNA Reverse Transcription Kit and
TaqMan Universal PCR Master Mix, no AmpErase UNG were ob-
tained from Applied Biosystems. Human macrophage CEH plasmid
(Accession No. AY268104, referred to as CEH hereafter) was con-
structed and characterized in our lab [38]. Unless noted, the rest
chemicals were purchased from Sigma-Aldrich (St. Louis, MO).
2.2. Animals
Six-week-old C57BL/6 mice (20 ± 3 g body weight, both gen-
ders) were obtained from the Jackson Laboratory (Bar Harbor, ME).
All the mice were kept in pathogen-free conditions with 12 h dark/
light cycle. All procedures were approved by the Virginia
Commonwealth University Institutional Animal Care and Use
Committee.
2.3. Isolation and culture of primary mouse hepatocytes
Primary mouse hepatocytes were isolated by collagenase-
perfusion technique as described previously [39]. The hepatocytes
were plated in collagen-coated wells in William’s E medium sup-
plemented with heat-inactivated FBS (10%), insulin (1.5 mM),
streptomycin (100 U/mL) and penicillin (100 U/mL). After 3 h, the
medium containing detached dead cells was aspirated and replaced
with fresh medium prior to any treatment. Unless noted, hepato-
cytes at ~90% conﬂuence were used throughout the experiments.
2.4. Evaluation of Gal-G5
2.4.1. Synthesis and characterization
Fifteen mg of PAMAM dendrimer G5 was dissolved in 0.1 M
sodium bicarbonate solution (pH 8.3e8.5) (10 mL), to which was
added 275 mg of Galactose-PEG-NHS (the molar ratio of Galactose-
PEG-NHS to G5 was approximately 15:1). The reaction proceeded
overnight at room temperature followed by dialysis and lyophili-
zation to obtain Gal-G5. Following the same chemistry, Gal-G5 and
G5 were reacted with IRDye 800CW NHS ester to form IRDye
800CW-labeled Gal-G5 and IRDye 800CW-labeled G5. To monitor
intracellular uptake and trafﬁcking in vitro, Gal-G5 and G5 were
labeled with FITC following a reported procedure [40]. 1H NMR
spectra were recorded on a Varian superconducting Fourier-
transform NMR spectrometer (Mercury-300) [20]. D2O was used
as the solvent.
2.4.2. Cytotoxicity assessment
Primary mouse hepatocytes were seeded in 48-well collagen-
coated cell culture plates (n ¼ 6) at a density of 5  104 cells/well
and cultured in William’s E medium containing 10% FBS overnight.
The cells were then incubated with increasing concentrations of
Gal-G5 or G5 (1e500 nM) for an additional 24 h, washed with DPBS
three times, and then subjected to WST-1 assay. In a separate
experiment, hepatocytes were treated 100 nM Gal-G5 or G5 for
24 h, rinsed with DPBS, stained with cell-impermeable ﬂuorescent
dye (DAPI) for 30 s, washed with DPBS again three times, and
imaged.
2.4.3. In vitro uptake by hepatocytes
Primary mouse hepatocytes were incubated with 50 nM FITC-
Gal-G5 or FITC-G5 for various lengths of time (2, 8, or 24 h). At
the end of each treatment, the cells were washed with DPBS three
times, ﬁxed with 4% buffered formalin PBS at room temperature for
30 min, and permeabilized with 0.15% Triton X-100 for 5 min. The
cells were washed with DPBS three times, counterstained with
DAPI, and imaged using a ﬂuorescence microscope.
In a separate experiment, primary mouse hepatocytes cultured
in the collagen-coated 60-mm dishes were incubated with 50 nM
FITC-Gal-G5 or FITC-G5 for 2, 8 or 24 h. At the end of each treat-
ment, the hepatocytes were collected and analyzed by using Canto-
BD FACSCanto™ II Analyzer (BD, USA) for quantiﬁcation of nano-
particle uptake in terms of mean ﬂuorescence intensity (MFI).
2.4.4. Competitive inhibition assay
Primary mouse hepatocytes were seeded on 4-chamber slides,
cultured overnight, and incubated with free galactose (0, 3 or
30 mM) for 30min followed by addition of 50 nM FITC-Gal-G5. After
2 h, the cells were counterstained with DAPI and imaged by using
ﬂuorescent microscopy. An identical experiment was conducted,
and the cells were collected for quantitative analysis of nano-
particle uptake by using ﬂow cytometry.
2.4.5. Uptake by mouse peritoneal macrophages
Mouse peritoneal macrophages were isolated following a pub-
lished protocol [41]. The cell pellets were collected after centrifu-
gation at 2000 rpm for 5 min, re-suspended inWilliam’s E medium
supplementedwith 10% FBS and 1% antibiotics and plated. The non-
adherent cells were removed after 2 h. The cells were incubated
with 50 nM FITC-G5 or FITC-Gal-G5 for 6 h and then processed for
ﬂuorescence imaging and ﬂow cytometry.
2.5. In vitro evaluation of Gal-G5/CEH complexes
2.5.1. Gel retardation assay
Gal-G5/CEH complexes (2.5, 5, 10, 20, 40 and 50, w/w) and G5/
CEH (0.25, 0.5, 1, 2, 4 and 8, w/w) were prepared following a pro-
cedure described earlier [23,42]. The complexes were mixed with
loading buffer and loaded onto a 0.8% agarose gel containing
ethidium bromide. The 1 kb DNA ladder (New England Biolabs,
Ipswich, MA) was included as a control. Electrophoresis was per-
formed in Tris-acetate-EDTA buffer at 100 V for 40 min. The DNA
bands were visualized with a UV-light system.
2.5.2. Colloidal stability test
Gal-G5/CEH (20:1, w/w) and G5/CEH (4:1, w/w)were used in the
rest studies. The hydrodynamic diameters of freshly prepared
complexes were measured at room temperature using a Malvern
Zetasizer Nano ZS90 (Malvern Instruments, Worcestershire, UK).
Furthermore, their size change during 24 h-incubation at 37 C was
monitored. The colloidal stability of the complexes following 24 h-
incubation at 37 C in PBS or PBS with 10% FBS was examined using
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gel retardation assay.
2.5.3. Transmission electron microscopy (TEM)
Gal-G5 and Gal-G5/CEH (20:1, w/w) sample suspensions were
loaded onto a 300 mesh carbon coated copper grid, air dried at
room temperature, and imaged under a transmission electron mi-
croscope (TEM) (JEM-3010, JEOL, Tokyo, Japan).
2.5.4. Intracellular trafﬁcking study
Label IT® Cy3® plasmid delivery control (referred to as Cy3
plasmid hereafter) was used a control. Hepatocytes were seeded in
2-well chamber slides and allowed to attach overnight. The cells
were incubated with FITC-Gal-G5/Cy3 plasmid (5 mg/0.25 mg) or
FITC-G5/Cy3 plasmid (1 mg/0.25 mg) in 500 mL of William’s E me-
diumwith 10% FBS at 37 C for 6 h. Afterwards, the medium in each
chamber was replaced with fresh growth medium containing 10%
FBS. The cells were cultured for an additional 6 or 24 h. At the end of
incubation, the cells were rinsed with DPBS, ﬁxed with 4% buffered
formalin PBS, permeabilized with 0.15% Triton X-100 and counter-
stained with DAPI. The cells were then imaged under a Zeiss LSM
700 confocal laser scanning microscope.
2.5.5. Transfection and biological activity studies
Hepatocytes were cultured in 6-well plates (~90% conﬂuence)
and transfected with Gal-G5/CEH (5 mg/0.25 mg), Gal-G5/empty
control vector (pCMV) (5 mg/0.25 mg), G5/CEH (1 mg/0.25 mg), or
G5/pCMV (1 mg/0.25 mg) in William’s E medium with 10% FBS for
24 h. After themedium in eachwell was replacedwith fresh growth
medium containing 10% FBS, the cells were cultured for an addi-
tional 24 or 48 h. CEH mRNA expression was quantiﬁed using
reverse transcription quantitative PCR (RT-qPCR) as described our
previous work [15,43,44]. CEH mRNA expression-mediated by Gal-
G5 or G5 relative to the expression observed in the hepatocytes
transfected with pCMV-mediated with the same carrier was
determined. CEH enzymatic activity was determined bymonitoring
the intracellular hydrolysis of HDL-delivered 3H-CE (HDL-3H-CE)
that was added to a separate set of hepatocytes following 24 h-
transfection. CEH enzymatic activity was assessed in terms of 3H-FC
accumulation in the cells, and the effects of increased CEH
expression on ﬂux of HDL-3H-CE to bile acids was assessed by
monitoring the release of 3H-bile acids (3H-BA) in the medium as
described earlier [15,43]. CEH enzymatic activity in non-transfected
hepatocytes was examined as control.
2.6. In vivo studies
2.6.1. Biodistribution
IRDye 800CW-labeled Gal-G5/CEH (20:1, w/w) or IRDye
800CW-labeled G5/CEH (4:1, w/w) was administered to C57BL/6
mice via tail vein injection. Both formulations were adjusted to
have an equivalent amount of total ﬂuorescent intensity (0.5 mg
IRDye 800CW/kg in 0.2 mL, balanced in osmolality with the addi-
tion of DPBS). At each pre-determined time point up to 168 h, a
group of 3 mice for each formulation were euthanized. Major or-
gans (heart, liver, spleen, lung and kidney) were harvested and
imaged using an Odyssey® Fc Imaging System (LI-COR, Nebraska
USA) at ex/em ¼ 780/800 nm followed by quantitative image
analysis of ﬂuorescence signals [45e47].
2.6.2. Tissue analysis of CEH mRNA expression
C57BL/6 mice received a bolus dose of Gal-G5/CEH (20:1, w/w)
or G5/CEH (4:1, w/w) (n ¼ 3) via tail vein injection (0.3 mg CEH/kg
in 200 mL, balanced in osmolality with the addition of DPBS) via tail
vein. At 24, 48, and 72 h-post injection, a group of 3 mice for each
formulation were scariﬁed. The major organs (heart, liver, lung,
kidney, and spleen) were harvested and processed for quantiﬁca-
tion of CEH gene expression using RT-qPCR. To distinguish CEH
expression between hepatocytes and resident macrophages (i.e.,
Kupffer cells) in the liver, one extra group of 3 mice treated with
Gal-G5/CEH or G5/CEH were sacriﬁced at 48 h-post injection, and
the hepatocytes and Kupffer cells in the liver were isolated and
subjected to RT-qPCR analysis [48].
2.6.3. Acute toxicity studies
C57BL/6 mice received a bolus dose of Gal-G5/CEH (20:1, w/w)
or G5/CEH (4:1, w/w) (0.6mg CEH/kg) (n¼ 3 per group) via tail vein
injection and maintained on chow diet. Untreated C57BL/6 mice
(n ¼ 3) were included as control. The mice were sacriﬁced at 24 h-
post administration. To assess hepatic toxicity, renal toxicity and
immunotoxicity of the formulations, the blood was collected and
analyzed for aspartate aminotransferase (AST), alanine amino-
transferase (ALT), blood urea nitrogen (BUN), interleukin 6 (IL-6)
and tumor necrosis factor-a (TNF-a) [33]. The tissues (heart, liver,
spleen, lung, and kidney) were processed for hematoxylin and
eosin (H&E) staining.
2.6.4. Flux of HDL-3H-CE to feces
C57BL/6 mice received a bolus dose of Gal-G5/CEH (20:1, w/w)
(0.6 mg CEH/kg) or plain Gal-G5 (12 mg/kg, equivalent to that used
in the Gal-G5/CEH group) (n ¼ 3 per group) via tail vein injection
and maintained on chow diet. At 48 h-post injection, one dose of
HDL-3H-CE (1.63  106 dpm/mouse) was administered to the mice
via tail vein injection. The mice were transferred to metabolic cages
and maintained for an additional 48 h until they were euthanized.
The blood, whole liver, gall bladder bile as well as feces were
collected. CEH expression in the liver was quantiﬁed with RT-qPCR.
Total radio activity in plasma, liver, and gall bladder was quantiﬁed
[48]. Furthermore, 3H-BA and 3H-FC were extracted from liver, gall
bladder bile and feces and quantiﬁed [15,17,49].
2.7. Statistical analysis
The data are expressed as mean ± SD. Student’s t-test was used
for statistical analysis, and P < 0.05 was considered statistically
signiﬁcant.
3. Results and discussions
3.1. Synthesis and characterization of Gal-G5
Gal-G5 (Fig. 1A) was synthesized by directly coupling Gal-PEG-
NHS to PAMAM G5 via NHS ester-amine reaction. 1H NMR was
used to check the purity and conjugation of galactose-modiﬁed
dendrimer. The spectrum (Fig. 1B) conﬁrms the relative high pu-
rity of the synthesized Gal-G5 as interfering proton peaks from
reactants, intermediates, or reaction solvent are not seen. The
methylene protons of branching units of G5 has multiple peaks
between 2.2 and 3.4 ppm. The repeat units of PEG from Gal-PEG-
NHS has a singlet peak at 3.6 ppm. According to the proton peak
integration, an average of 11 Gal-PEG chains were conjugated to G5.
Gal-G5 showed enhanced cytocompatibility. It remained
nontoxic to hepatocytes when the concentration was increased to
100 nM (Fig. 2A). In contrast, the toxicity of G5 at 100 nM was
strong, causing cell viability to drop to 62%. The cell viability was
further decreased to 30% by G5 at 500 nM. In contrast, 65% of the
cells remained viable in the presence of 500 nM Gal-G5, indicating
its relatively higher cytocompatibility. After DAPI staining, a sig-
niﬁcant fraction of dead cells are clearly seen in the G5/100 nM
group (Fig. 2B), whereas such observation is not seen in the Gal-G5/
100 nM group. Galactose functionalized G5 obtained signiﬁcantly
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improved cytocompatibility likely due to the effective charge
shielding effect of PEG chains and decreased number of amines on
the dendrimer surface as reported in the literature [50e52].
3.2. Hepatocyte-speciﬁcity of Gal-G5 in vitro
Cellular uptake kinetics of FITC-G5 (50 nM) and FITC-Gal-G5
(50 nM) by primary hepatocytes was monitored by using ﬂuores-
cence microscopy (Fig. 3A). Increased cellular uptake of nano-
particles with increasing incubation time was observed in both
groups, but a much stronger ﬂorescence signal was seen in the
FITC-Gal-G5 group at any time point as compared to FITC-G5.
Consistent with the imaging data, FITC-Gal-G5 shows much
higher cellular uptake (measured as mean ﬂuorescent intensity,
MFI) (Fig. 3B). For instance, the MFI of FITC-Gal-G5 is 7000 ± 300 at
24 h, which is ten-fold stronger than that of FITC-G5.
The uptake of FITC-Gal-G5 via ASGPR was conﬁrmed using
competitive inhibition assay. As shown in Fig. 4A, ﬂuorescence
Fig. 3. Gal-G5 shows enhanced uptake by hepatocytes. Primary mouse hepatocytes
were incubated with 50 nM FITC-Gal-G5 or FITC-G5 for various lengths of time (2, 8, or
24 h) and then subjected to ﬂuorescent imaging and ﬂow cytometry analysis. (A)
Representative ﬂuorescence images. (B) Quantiﬁcation of nanoparticle uptake as a
function of time reported as MFI of FITC. n ¼ 3, *P < 0.05, **P < 0.01.Fig. 1. Chemical structure and characterization of Gal-G5. (A) PAMAM dendrimer G5
functionalized with hepatocyte speciﬁc ligand galactose alone or along with ﬂuores-
cence dye (FITC or IRDye 800CW). (B) 300 MHz 1H NMR spectrum of Gal-G5 in D2O.
multiple proton peaks 2 between 2.2 and 3.4 ppm are assigned to the methylene
protons of G5 branching units, while a singlet peak 1 at 3.6 ppm is assigned to the
ethylene protons of the repeat units of PEG. D2O has a proton peak at 4.8 ppm.
Fig. 2. Gal-G5 shows high cytocompatibility. Primary mouse hepatocytes were treated with Gal-G5 or G5 at the indicated concentrations for 24 h and then assessed with the WST-
1 assay for viability. (A) Gal-G5 is more tolerated by primary mouse hepatocytes. *P < 0.05 (n ¼ 5). (B) Representative images of the cells treated with G5 or Gal-G5 at 100 nM. The
cells stained with ﬂuorescent dye DAPI are dead cells due to the lack of an intact cell membrane. Scale bar: 20 mm.
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signal of FITC-Gal-G5 was reduced signiﬁcantly with increasing
exogenous galactose concentration. Flow cytometry was used to
quantify the uptake, and the MFI values are shown in Fig. 4B.
Compared to the uptake observed in the absence of galactose,
signiﬁcantly reduced uptake was seen in the presence of 3 mM free
galactose (24% decrease, P < 0.05) and 30 mM (77% decrease,
P < 0.01). Free galactose selectively binds ASGPR. The presence of
free galactose suppressed the uptake of FITC-Gal-G5 because it
bound to the receptors and blocked the access of FITC-Gal-G5 to the
same receptors. These data clearly demonstrate that the galactose
functionalization of G5 effectively increased the uptake by hepa-
tocytes through the ASGPR that has a high afﬁnity for galactose.
These observations are consistent with other studies reporting
galactose-mediated increase in hepatocyte uptake of nanoparticles
[53e55].
Additionally, the effect of galactose modiﬁcation on the uptake
of G5 bymouse peritoneal macrophages, one of themost aggressive
scavengers, was investigated. The results showed that the uptake of
Gal-G5 by macrophages was 4-fold lower than that of plain G5
(Fig. 5A and 5B). The reduced uptake by macrophages is likely due
to low expression of galactose receptor ASGPR on themacrophages.
In addition, PEGylation of Gal-G5 helped reduce non-speciﬁc up-
take due to the surface charge shielding effect [56e59].
3.3. Characterization of dendrimer/CEH complexes
Formation of dendrimer/CEH complexes was initially evaluated
by using gel retardation assay. As shown in Fig. 6A, G5 and CEH
plasmid form stable complexes at a weight ratio of 4 or higher. A
weight ratio of 20 or higher is needed for Gal-G5 to complex with
CEH plasmid stably, presumably due to the charge shielding effect
of long PEG chains evidenced by zeta potential decrease from
30mV for G5 to 2 mV for Gal-G5. Nonetheless, the DNA compaction
ability of Gal-G5 is deemed sufﬁcient. Hydrodynamic size results
(Fig. 6B) show that size signiﬁcantly increased from ~10 nm for Gal-
Fig. 4. Receptor-mediated endocytosis of Gal-G5 by hepatocytes: competitive inhibition study. Freshly isolated mouse hepatocytes were pre-incubated with galactose (0, 3, or
30 mM) for 30 min at 37 C and then with 50 nM Gal-G5 for 2 h. The uptake of FITC-Gal-G5 was monitored by ﬂuorescence microscopy (A) and quantiﬁed by ﬂow cytometry (B).
n ¼ 3, *P < 0.05, and **P < 0.01.
Fig. 5. Gal-G5 shows reduced uptake by macrophages. Mouse peritoneal macro-
phages were incubated with 50 nM FITC-Gal-G5 or FITC-G5 for 6 h and then subjected
to ﬂuorescence imaging or ﬂow cytometry analysis. (A) Representative ﬂuorescence
images. (B) Quantiﬁcation of nanoparticle uptake reported as MFI of FITC. n ¼ 3,
**P < 0.01.
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G5 alone to 114.9 nm for Gal-G5/CEH. As shown in the TEM images,
the Gal-G5/CEH complexes have a much larger size than Gal-G5.
The colloidal stability of these complexes in salt solution (PBS)
as well as in the presence of serumwas tested. As shown in Fig. 6C,
no signiﬁcant change in the hydrodynamic diameter of complexes
at 37 C for 24 h suggested that formulation stability of complexes
can be maintained for at least 24 h. Fig. 6D showed that naked
plasmid DNA (lane 3) was completely digested in the presence of
serum likely by nucleases during the 24 h-incubation. In contrast,
both types of dendrimer/CEH complexes were not destroyed by
serum (lane 5 for G5/CEH and lane 7 for Gal-G5/CEH) and were
retained in the loading wells similarly to the corresponding con-
trols in the absence of serum (lane 4 for C5/CEH and lane 6 for Gal-
G5/CEH). These results demonstrate that both G5 and Gal-G5 are
able to protect the complexed DNA from degradation by serum
nucleases and maintain good colloidal stability, supporting their
suitable use in in vitro and in vivo studies.
3.4. Intracellular trafﬁcking of complexes
Effective dissociation and subsequent movement of DNA to the
nucleus is critical for expression of the delivered gene. Intracellular
localization and dissociation FITC-Gal-G5/Cy3-labeled plasmid and
FITC-G5/Cy3 plasmid were examined. After 6 h, Cy3 plasmid was
tightly complexed with both vectors. Dissociation of Cy3-plasmid
from FITC-Gal-G5 became evident at 24 h, while no appreciable
dissociation of Cy3 plasmid and FITC-G5 was observed (Fig. 7,
highlighted, clear separation of green FITC-Gal-G5 and red Cy3
plasmid, and some red plasmid also entered the nucleus mediated
by FITC-Gal-G5). The dissociation was attributed to the weakened
electrostatic interactions between dendrimer and plasmid by long
PEG spacer. It was a critical step before released plasmid could
further translocate into the nucleus for transcription and trans-
lation. Those observations are consistent with facilitated gene
transfection delivered by PEGylated-PAMAM dendrimer reported
by other researchers [60,61].
3.5. Increased CEH expression and activity in hepatocytes mediated
by Gal-G5/CEH complex in vitro
To directly examine whether galactose functionalization indeed
increases the ability of Gal-G5 to deliver CEH expression vector to
hepatocytes in vitro, CEH mRNA expression in hepatocytes was
quantiﬁed by using RT-qPCR. CEH expression vector where CEH
expression was driven by a constitutive Cytomegalo virus (CMV)
promoter was used along with empty vector pCMV serving as a
control. Fold increase in CEH mRNA expression was determined
relative to the expression observed in hepatocytes treated with
dendrimer/pCMV. It should be noted that no Ct value was obtained
when RNA from hepatocytes treated with G5/pCMV or Gal-G5/
pCMV complexes since the PCR probes used were speciﬁc for hu-
man CEH. As shown in Fig. 8A, expression of CEH delivered by Gal-
G5 was about 2- and 6-fold higher than that by G5 (P < 0.01) after
24 and 48 h exposure, respectively, demonstrating the higher ef-
ﬁciency of CEH delivery achieved with Gal-G5.
We have earlier demonstrated that increase in hepatic CEH not
only leads to the increased hydrolysis of HDL-CE but also increases
the ﬂux of cholesterol from HDL-CE to bile acids providing the
mechanism underlying the anti-atherosclerotic effects of hepatic
CEH [17,44]. The long term objective of developing a non-viral
platform for targeted delivery of CEH to the liver is to establish it
as a novel anti-atherosclerotic strategy. Towards this goal, it is
critical to establish that Gal-G5-delivered CEH is biologically active
or functional. To examinewhether increased CEHmRNA expression
leads to increase in intracellular CE hydrolysis, conversion of
HDL-3H-CE to 3H-FC and ﬁnal conversion of 3H-FC to 3H-BA was
monitored. Consistent with the increased CEH mRNA expression,
compared to hepatocytes exposed to G5/CEH, signiﬁcantly higher
hydrolysis of HDL-CE was noted in hepatocytes exposed to Gal-G5/
CEH complexes (Fig. 8B, 70 ± 4% versus only 39 ± 7%, P < 0.05).
Furthermore, increased conversion of HDL-CE derived FC to bile
acids was also noted in the hepatocytes treated with Gal-G5/CEH
complexes (Fig. 8C, 417 ± 100% versus 182 ± 63%, P < 0.05).
Consistent with our earlier data showing increased conversion of
HDL-CE to BA following adenovirus-mediated overexpression of
CEH or transgenic CEH overexpression in hepatocytes [15,17,44],
these data conﬁrm that Gal-G5-mediated delivery of CEH gene
leads to the elimination of HDL-CE to BA.
3.6. Enhanced liver-speciﬁc delivery in vivo
The ﬁnal step in establishing the validity of galactose function-
alized G5 as a platform for delivery of CEH or any other expression
vector to the liver to modulate in vivo expression, it is important to
Fig. 6. Characterization of dendrimer/CEH complexes. (A) Gel retardation assay on G5/CEH and Gal-G5/CEH complexes freshly prepared at different weight ratios. M: the DNA
ladder. The stable complexes remained immobile as highlighted. (B) DLS (room temperature) and TEM images of Gal-G5 and freshly prepared Gal-G5/CEH complexes (20:1, w/w).
Some Gal-G5 particles are pointed with arrows and Gal-G5/CEH complexes are highlighted in red circles. (C) Hydrodynamic size change of Gal-G5/CEH (20:1, w/w) and G5/CEH (4:1,
w/w) at 37 C in PBS over a period of 24 h. (D) Gel retardation assay on G5/CEH (4:1, w/w) and Gal-G5/CEH (20:1, w/w) following 24 h-incubation 37 C in PBS or PBS with 10% FBS.
Lane 1: the DNA ladder; Lane 2: CEH in PBS; Lane 3: CEH in 10% FBS; Lane 4: G5/CEH in PBS; Lane 5: G5/CEH in 10% FBS; Lane 6: Gal-G5/CEH in PBS; Lane 7: Gal-G5/CEH in 10% FBS.
Both G5/CEH and Gal-G5/CEH maintained good colloidal stability and did not release CEH plasmid as highlighted. (For interpretation of the references to colour in this ﬁgure legend,
the reader is referred to the web version of this article.)
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not only demonstrate selective uptake by liver but also show that
such a delivery does not induce toxicity. For this purpose, time-
dependent in vivo bio-distribution of IRDye 800CW-labeled Gal-
G5/CEH and IRDye 800CW-labeled G5/CEH was monitored after
intravenous injection. Fig. 9A shows that IRDye 800CW-labeled
Gal-G5/CEH rapidly targeted liver after 1 h intravenous adminis-
tration and the accumulation gradually increased with highest in-
tensity in liver seen after 48 h. The IRDye 800CW ﬂuorescence
intensity persisted for at least 7 days post-administration. This
higher liver accumulation of IRDye 800CW-labeled Gal-G5/CEH in
comparison to the IRDye 800CW-labeled G5/CEH was consistent
with higher in vitro hepatocyte uptake described before validating
the liver-speciﬁc delivery due to galactose functionalization.
Compared to G5, PEG modiﬁcation of galactose resulted in a
decrease of the passive reticuloendothelial system (RES) uptake by
spleen and renal clearance consistent with known effects of
PEGylation, namely, enhanced biocompatibility and non-
immunogenicity, and increased blood circulation time by
reducing opsonization by proteins and hindering the uptake by
macrophages in the RES. Similar accumulation in the RES organs
(liver and spleen) was observed in the mice administrated with
IRDye 800CW-labeled G5/CEH. Furthermore, obvious accumulation
of ﬂuorescent intensity was also observed in kidney from both
groups. This is likely due to ﬁltration and secretion of nanosized
dendrimer (less than 10 nm) after dissociation of complexes.
However, compared with the group treated with IRDye 800CW-
labeled G5/CEH, the lower ﬂuorescent signal in kidney from the
IRDye 800CW-labeled Gal-G5/CEH-treated group within 48 h was
probably attributed to extended circulation time induced by
PEGylation. These data not only are consistent with in vitro obser-
vation but also clearly demonstrate the ability of Gal-G5 to selec-
tively deliver gene to the liver. The ﬂuorescence intensity of each
tissue was quantitatively analyzed using CLx infrared imaging
system software and plotted in Fig. 9B.
3.7. Gal-G5 mediated liver-speciﬁc delivery increases CEH
expression in vivo
In vivo CEH gene expression analysis (Fig.10A) revealed that Gal-
G5/CEH resulted in much higher CEH expression (shown as copy
number of CEH mRNA) in liver in comparison to the G5/CEH at all
three time points. The highest CEH expression in liver was seen in
the group-treated with Gal-G5/CEH at 48 h, which was around 3
fold (P < 0.01) higher than G5/CEH group. Higher CEH expression in
spleen was observed among the mice-treated with G5/CEH post-
48 h injection; the decrease in CEH copy number in liver at 72 h
could be related to mRNA stability/degradation. CEH expression in
other tissues such as heart, lung and kidney was very low for both
complexes consistent with low accumulation in both heart and
lung. Despite the accumulation of near-infrared (NIR) dye in the
kidney likely due to ﬁltration/accumulation of un-complexed or
free dendrimer, there was no signiﬁcant expression of CEH indi-
cating negligible delivery of CEH expression vector. While the Gal-
G5/CEH complexes mediated increase in CEH expression seen here
is 100-fold lower than the transient adenovirus-mediated CEH
expression in liver previously achieved by our lab (~5  106 copies/
mg total RNA) [17], only a two-fold increase in CEH activity in liver-
speciﬁc CEH transgenic mice was sufﬁcient to attenuate diet-
Fig. 7. Intracellular dissociation of Cy3 plasmid from G5 or Gal-G5 in mouse hepatocytes. Primary mouse hepatocytes were incubated with FITC-G5/Cy3 plasmid (4:1, w/w) (A)
or FITC-Gal-G5/Cy3 plasmid (20:1, w/w) (B) in William’s E medium supplemented with 10% FBS for 6 h. The medium was replaced with fresh medium containing 10% FBS, and the
hepatocytes were incubated for an additional 6 or 24 h. At the end of the incubation, the cells were rinsed with DPBS, and the nuclei stained with DAPI and imaged by using confocal
microscopy (630). Blue, DAPI; Green, FITC; Red, Cy3. A magniﬁed view of the area outlined by the smaller squared box is presented in the top right corner to show dissociation of
plasmid from the carrier. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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induced atherosclerosis in Ldlr/ mice [44]. Therefore, this non-
viral gene delivery platform still holds promise as a novel alterna-
tive with safe application, low cost and simple construction. Liver
consists of hepatocytes as well as resident macrophages, i.e.,
Kupffer cells. Although in vitro data showed negligible uptake of
Gal-G5 by isolated macrophages, relative expression of CEH was
further examined in hepatocytes and Kupffer cells for comparison.
As shown in Fig. 10B, there was signiﬁcantly higher increase in CEH
expression in hepatocytes versus Kupffer cells in the mice-treated
with Gal-G5/CEH compared to G5/CEH (350-fold higher for Gal-
G5/CEH versus 5-fold higher for G5/CEH, P < 0.01). Taken
together with the in vitro data, these results conﬁrm the
hepatocyte-speciﬁc delivery of CEH by Gal-G5.
3.8. In vivo tissue safety of Gal-G5/CEH
Acute systemic toxicity and inﬂammatory reaction was investi-
gated 24 h after intravenous administration to examine the
biocompatibility of two kinds of complexes. There were no obvious
histological differences between the major organs of treated and
untreated mice (Fig. 11). Plasma levels of ALT and AST for liver
toxicity, BUN for kidney toxicity and TNF-a and IL-6 for induction of
inﬂammatory reaction were determined and the data are summa-
rized in Table 1. Gal-G5/CEH group showed excellent tissue
compatibility. No signiﬁcant differences in these parameters were
seen between the Gal-G5/CEH group and the untreated control
group. However, signiﬁcant increases in the levels of ALT, AST and
IL-6were observed in the G5/CEH. These results suggest the toxicity
of G5/CEH to tissues or organs including the metabolically active
liver. Given the toxicity and low hepatocyte speciﬁcity of G5/CEH,
only Gal-G5/CEH was evaluated for in vivo anti-atherogenic effects.
3.9. Gal-G5 mediated delivery of CEH to liver increases the ﬂux of
HDL-CE to bile and feces in vivo
The mechanism underlying the anti-atherogenic effects of
Fig. 8. Delivery of CEH plasmid via Gal-G5 results in increased CEH expression and associated biological activity. (A) CEH expression enhanced by Gal-G/CEH. Primary mouse
hepatocytes were treated with G5/pCMV (4:1, w/w) (control), G5/CEH (4:1: w/w), Gal-G5/pCMV (20:1, w/w) (control) or Gal-G5/CEH (20:1, w/w) for 24 h. Following replacement
with fresh growth medium, the hepatocytes were incubated for an additional 24 or 48 h. At the end of the treatment, total RNA was isolated and CEH gene expression was
determined by using RT-qPCR. CEH expression induced by G5/CEH or Gal-G5/CEH relative to that induced by the corresponding control is presented. n ¼ 3, *P < 0.05 and **P < 0.01.
(B) Intracellular hydrolysis of HDL-CE promoted by Gal-G5/CEH. Primary mouse hepatocytes were incubated with G5, Gal-G5, G5/CEH (4:1, w/w), or Gal-G5/CEH (20:1, w/w) for
24 h. Then the hydrolysis of HDL-3H-CE in each group was monitored. n ¼ 3, *P < 0.05. (C) The ﬂux of FC to bile acids as a result of CEH-mediated hydrolysis of HDL-3H-CE was
assessed by monitoring the appearance of 3H-BA in the culture medium. n ¼ 3, *P < 0.05.
Fig. 9. Enhanced in vivo liver uptake of Gal-G5. C57BL/6 mice were administered with IRDye 800CW-labeled Gal-G5/CEH or IRDye 800CW-labeled G5/CEH via tail vein injection.
(A) Major organs were harvested at indicated time points and imaged using the Odyssey® Fc Imaging System at ex/em ¼ 780/800 nm (heart, liver, spleen, lung and kidney, from left
to right). (B) Quantitative analysis of ﬂuorescent signal intensities of the major organs at different time points (n ¼ 3).
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hepatic CEH is its ability to hydrolyze CE delivered by HDL and
enhance the ﬂux of resulting FC to bile acids for biliary secretion
and elimination in feces. To determine whether Gal-G5-mediated
delivery of CEH expression vector modulates this critical step
in vivo, the ﬂux of radiolabeled-CE from HDL in circulation to the
liver and then to bile acids and feces was monitored. It must be
emphasized that the 3H-label in these studies is associated with
the cholesterol moiety of CE permitting the tracking of this label to
monitor the hydrolysis of HDL-CE in the liver, its conversion to bile
acids and ﬁnal secretion into feces. As shown in Fig. 12, Gal-G5/
CEH signiﬁcantly increased the CEH expression in liver
compared with the blank vector Gal-G5 (P < 0.01, Panel A).
Following intravenous administration of HDL-3H-CE, lower radio-
activity in plasma (P < 0.05, Panel B) and higher radioactivity in
whole liver (P < 0.05, Panel C) were observed in the Gal-G5/CEH
group, suggesting that the increased CEH expression in the liver
increased the clearance of HDL-3H-CE from the blood and corre-
sponding increase in uptake by the liver. It should be noted that
radioactivity associated with the liver is the sum of 3H-CE deliv-
ered to the liver via HDL receptor SR-BI and the downstream
metabolic products of 3H-CE including 3H-FC and 3H-BA. To
directly evaluate the effects of increased CE expression in the liver,
radioactivity associated with hepatic FC and BA was determined.
Consistent with the increased expression of CEH in mice treated
with Gal-G5/CEH complexes, higher radioactivity was associated
with hepatic FC and BA (P < 0.05, Panel D) indicating that
increased CEH expression led to increase in intracellular CE hy-
drolysis into FC and ﬁnal conversion of FC to BA. Following syn-
thesis, BA is secreted into bile that is stored in the gall bladder and
timely released into the intestine to facilitate digestion. To
examine the effects of increased CEH expression in the liver in
mediating the ﬂux of cholesterol from HDL to biliary BA, radio-
activity associated with BA extracted from gall bladder bile was
monitored. Signiﬁcantly higher level of radiolabel was associated
with biliary BA in Gal-G5/CEH complex-treated mice (P < 0.05,
Panel E and Panel F); there was no signiﬁcant difference between
radiolabel associated with FC. Biliary BA and FC are ﬁnally secreted
into feces and this represents the only physiological mechanism
for ﬁnal elimination of cholesterol from the body. It is noteworthy
that lack of enzymes to cleave the steroid nucleus necessitates the
conversion of hydrophobic cholesterol into hydrophilic bile acids
by hydroxylation to facilitate elimination in feces. Therefore, any
mechanism that can stimulate removal of cholesterol returning to
Fig. 11. In vivo delivery of CEH by Gal-G5 does not cause tissue toxicity. C57BL/6
mice were injected (i.v.) with Gal-G5 or G5, and major organs were harvested 24 h
post-injection. Untreated C57BL/6 mice were used as control. H&E-stained sections of
the major organs are shown.
Fig. 10. Enhanced in vivo CEH expression in hepatocytes in the liver by Gal-G5/CEH. (A) CEH expression in the major organs at selected time points, i.e., 24, 48 and 72 h post-
injection was quantiﬁed with RT-qPCR. n ¼ 3, **P < 0.01. (B) In a parallel experiment, hepatocytes and Kupffer cells were isolated from the livers of the treated mice at 48 h-post
injection, and CEH expression in the isolated cells was quantiﬁed with RT-qPCR. A signiﬁcant increase in CEH expression in hepatocyte relative to that in Kupffer cells was achieved
by Gal-G5/CEH. n ¼ 3, **P < 0.01.
Table 1
Quantiﬁcation of hematological biomarkers of hepatic and renal toxicity as well as cytokine biomarkers of immunotoxicity.
Treatment AST (U/L) ALT (U/L) BUN (mg/dL) IL 6 (ng/mL) TNF-a (ng/mL)
Control 65 ± 10.3 34 ± 3.5 22 ± 0.6 1.1 ± 0.10 0.6 ± 0.11
G5/CEH 315 ± 114.9** 169 ± 81.8** 27 ± 6.1 3.6 ± 0.20** 0.7 ± 0.12
Gal-G5/CEH 71 ± 13.2 37 ± 8.2 26 ± 5.6 1.6 ± 0.05 0.5 ± 0.05
Note: n ¼ 3, **P < 0.01 vs. the control.
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the liver from the peripheral tissues (as CE in HDL particle),
including arterial-plaque associated macrophage foam cells, will
potentially reduce cholesterol burden and be anti-atherogenic.
Therefore, as a ﬁnal step, effects of Gal-G5 delivered CEH expres-
sion vector on fecal elimination of cholesterol derived from HDL
was monitored. Signiﬁcantly higher radioactivity was also associ-
ated with fecal BA and FC in mice injected with Gal-G5/CEH
complex compared with mice injected with Gal-G5 (P < 0.05,
Panel G). These data are consistent with earlier studies from our
laboratory showing increased ﬂux of HDL-CE to bile and feces by
hepatic over-expression of CEH [15,17,44,48] that promotes intra-
cellular hydrolysis of HDL delivered CE and thus enhances the
elimination of cholesterol from the body. Indeed, transgenic over
expression of CEH attenuates atherosclerosis in Ldlr/ mice and
these data provide a non-genetic/non-viral approach to enhancing
the expression of CEH in the liver as a potentially novel anti-
atherogenic strategy.
4. Conclusions
Inhibition of pathological processes central to the development
of disease, by pharmacologically active small molecules [62] or
genetic manipulation by small interfering RNA (siRNA)/microRNA
(miRNA)/antisense oligonucleotides (ASOs) [63e65], is the most
widely accepted strategy to reduce the progression of diseases.
However, enhancing an endogenous biological process that is
necessary for the prevention of disease progression, and more
importantly the reversal of the disease, has proven to be chal-
lenging mainly because of the lack of suitable platforms for the
introduction of the critical gene required to increase the affected
pathway. Based on the signiﬁcant residual CVD risk present despite
reaching the target LDL cholesterol levels and failure of risk
reduction by merely increasing HDL cholesterol levels has shifted
the paradigm from lipoprotein associated cholesterol to ﬂux of
cholesterol from arterial plaque associated macrophages to liver
and ﬁnal elimination from the body [66]. The fact that cholesterol is
carried within the lipoproteins as CE but only FC is secreted in bile
either directly or following conversion to bile acids underscores the
importance of hepatic CE hydrolysis and earlier studies from our
laboratory have established the anti-atherogenic role of hepatic
CEH. Currently, endogenous regulation of CEH remains largely
unknown in mice or humans although reduced CEH expression is
reported in human carotid artery plaques [4]. With the objective to
address the as yet unmet need for novel strategies for enhancing
the removal of cholesterol from body, the data presented herein
demonstrates the suitability of Gal-G5 to deliver CEH to the liver
and increase the ﬂux of cholesterol from HDL-CE to FC and bile
acids by increasing CE hydrolysis within the hepatocytes. Further-
more, functionalization of G5 with galactose not only increases
liver-speciﬁc delivery, but use of long PEG spacer for galactose also
Fig. 12. Increased CEH expression in the liver promotes RCT in vivo. WT C57BL/6 mice were administered with Gal-G5 or Gal-G5/CEH via tail vein injection. After 48 h, mice were
intravenously injected with [3H]-CE-labeled HDL. After an additional 48 h, blood, liver, gall bladder bile and feces were collected and analyzed. Radioactivity data (n ¼ 3) are
presented as the percentage of the total injected radiolabeled dose. (A) CEH expression in the liver (**P < 0.01); (B) radioactivity in plasma (*P < 0.05); (C) total radioactivity in the
liver (*P < 0.05); (D) 3H-FC and 3H-BA in the liver (*P < 0.05); (E) total radioactivity in gall bladder bile (*P < 0.05); (F) 3H-FC and 3H-BA in gall bladder bile (*P < 0.05); (G) 3H-FC and
3H-BA in feces (*P < 0.05).
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reduces the toxicity associated with high positive charges on the
surface of unmodiﬁed G5. The development of this relatively non-
toxic and efﬁcient liver-speciﬁc gene delivery platform is an
encouraging step towards the clinical translation of strategies
based on enhancing removal of cholesterol from the body to reduce
the existing atherosclerotic plaque burden (or plaque regression)
for which no therapeutics are currently available. It is noteworthy
that hepatocyte-speciﬁc CEH over-expression signiﬁcantly attenu-
ates western diet-induced atherosclerosis without having any ef-
fect on plasma lipoprotein proﬁle [44]. Future studies will be
focused on the pre-clinical evaluation of Gal-G5/CEH-mediated
increase in cholesterol elimination from the body and its impact on
reducing atherosclerotic plaque burden.
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